LESS THAN 5% OF REAL-LIFE PATIENTS WHO SWITCH FROM IV TO SC ABATACEPT IN REAL-WORLD CLINICAL PRACTICE SUBSEQUENTLY SWITCH BACK TO THE IV FORMULATION
No Thumbnail Available
Identifiers
Date
2017-06-01
Authors
Alten, R.
Lorenz, H-M.
Mariette, X.
Nuesslein, H.
Galeazzi, M.
Navarro, F.
Chartier, M.
Heitzmann, J.
Rauch, C.
Le Bars, M.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Bmj publishing group
Metrics
Export
Abstract
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
Subcutaneous formulation